An<unk>  (also called an<unk> ue) is any of several types of<unk>  (medication) that are altered forms of the hormone<unk> , different from any occurring in nature, but still available to the human body for performing the same action as human<unk>  in terms of controlling blood glucose levels in diabetes. Through genetic engineering of the underlying DNA, the amino acid sequence of<unk>  can be changed to alter its ADME (absorption, distribution, metabolism, and excretion) characteristics. Officially, the U.S. Food and Drug Administration (FDA) refers to these agents as<unk>  receptor ligands (because, like<unk>  itself, they are ligands of the<unk>  receptor), although they are usually just referred to as<unk> s. These modifications have been used to create two types of<unk> s: those that are more readily absorbed from the injection site and therefore act faster than natural<unk>  injected subcutaneously, intended to supply the bolus level of<unk>  needed at mealtime (prandial<unk> ; and those that are released slowly over a period of between 8 and 24 hours, intended to supply the basal level of<unk>  during the day and particularly at nighttime (basal<unk> . The first<unk> <unk>  Lispro rDNA) was approved for human therapy in 1996 and was manufactured by Eli Lilly and Company.
Insulin analog
Galactagogue
Caloric restriction mimetic
Sugar substitute
Glucuronide
17α-Alkylated anabolic steroid
Glucose-elevating agent
Antiglucocorticoid